Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.19.3.a.u2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenues $ 314 $ 651 $ 422 $ 696
Operating expenses:        
Research and development (related party of $0, $285, $97 and $544), net of grant income of $0, $37, $0 and $37, respectively 888 1,273 1,865 2,397
General and administrative (related party of $304, $311, $572 and $526) 2,581 3,393 5,567 6,264
Total operating expenses 3,469 4,666 7,432 8,661
Operating loss (3,155) (4,015) (7,010) (7,965)
Other income (expense):        
Interest expense - related party (615) (476) (1,235) (952)
Interest income 4 23 8 44
Royalty income (expense) 2 (2) 9 4
Total other income (expense) (609) (455) (1,218) (904)
Consolidated net loss (3,764) (4,470) (8,228) (8,869)
Net loss attributable to noncontrolling interest 2 1 3 2
Net loss attributable to iBio, Inc. (3,762) (4,469) (8,225) (8,867)
Deemed dividends - down round of Series A Preferred and Series B Preferred (21,560) 0 (21,560) 0
Preferred stock dividends- iBio CMO Preferred Tracking Stock (65) (65) (131) (131)
Net loss available to iBio, Inc. (25,387) (4,534) (29,916) (8,998)
Comprehensive loss:        
Consolidated net loss (3,764) (4,470) (8,228) (8,869)
Other comprehensive income (loss) - foreign currency translation adjustments 1 1 (1) 0
Comprehensive loss $ (3,764) $ (4,469) $ (8,229) $ (8,869)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.69) $ (0.24) $ (1.02) $ (0.49)
Weighted-average common shares outstanding - basic and diluted 36,917 18,688 29,420 18,291